Cott (TSE:PRM – Get Free Report) was upgraded by stock analysts at William Blair to a “strong-buy” rating in a research note issued on Thursday, Zacks.com reports.
Separately, Raymond James lowered shares of Cott from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 2nd.
Get Our Latest Analysis on PRM
Cott Price Performance
Cott Company Profile
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
Recommended Stories
- Five stocks we like better than Cott
- How Investors Can Find the Best Cheap Dividend Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- Using the MarketBeat Stock Split Calculator
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Compound Interest and Why It Matters When Investing
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Cott Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cott and related companies with MarketBeat.com's FREE daily email newsletter.
